Phase III trial of Urocidin (Endo Pharma) for Bladder Cancer is abandoned

A Phase III clinical trial with Urocidin (mycobacterial cell wall DNA complex), from Endo Pharma, in non-muscle-invasive Bladder Cancer is being discontinued. The trial, a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to compare Urocidin with mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscle-invasive Bladder Cancer, was being run by the Company's global licensing partner, Endo Pharmaceuticals (Endo), a subsidiary of Endo Health Solutions. This is the drug's second Phase III trial, which began in May 2011. However it has not been recruiting at the expected rate and, after recent discussions with the FDA regarding the current clinical trial design, Endo has decided to end the study before its scheduled completion. Endo and Bioniche are jointly considering potential next steps for the program.